BidaskClub upgraded shares of Insulet (NASDAQ:PODD) from a hold rating to a buy rating in a report published on Friday morning.
PODD has been the subject of several other reports. Zacks Investment Research downgraded Insulet from a buy rating to a hold rating in a report on Saturday, November 11th. Barclays reissued a buy rating and issued a $78.00 target price on shares of Insulet in a report on Wednesday, December 13th. Oppenheimer set a $82.00 target price on Insulet and gave the company a hold rating in a report on Thursday, February 22nd. UBS Group raised Insulet from a market perform rating to an outperform rating in a report on Monday, January 8th. Finally, Raymond James Financial raised Insulet from a market perform rating to an outperform rating and set a $80.00 target price for the company in a report on Monday, January 8th. One research analyst has rated the stock with a sell rating, seven have given a hold rating and thirteen have given a buy rating to the stock. The company presently has a consensus rating of Buy and an average price target of $73.24.
Shares of Insulet (NASDAQ PODD) opened at $83.15 on Friday. The company has a current ratio of 6.24, a quick ratio of 5.85 and a debt-to-equity ratio of 3.57. Insulet has a fifty-two week low of $38.43 and a fifty-two week high of $83.56. The firm has a market capitalization of $4,840.00, a price-to-earnings ratio of -180.76 and a beta of 1.56.
In other news, COO Shacey Petrovic sold 1,319 shares of the firm’s stock in a transaction on Tuesday, March 6th. The stock was sold at an average price of $76.81, for a total value of $101,312.39. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director David A. Lemoine sold 641 shares of the firm’s stock in a transaction on Tuesday, March 6th. The shares were sold at an average price of $76.81, for a total value of $49,235.21. The disclosure for this sale can be found here. Company insiders own 2.60% of the company’s stock.
Hedge funds have recently made changes to their positions in the company. Schwab Charles Investment Management Inc. increased its position in shares of Insulet by 4.1% in the fourth quarter. Schwab Charles Investment Management Inc. now owns 276,930 shares of the medical instruments supplier’s stock valued at $19,109,000 after buying an additional 10,989 shares in the last quarter. Point72 Asset Management L.P. purchased a new position in shares of Insulet in the third quarter valued at $33,373,000. Bank of New York Mellon Corp increased its position in shares of Insulet by 6.7% in the third quarter. Bank of New York Mellon Corp now owns 289,027 shares of the medical instruments supplier’s stock valued at $15,919,000 after buying an additional 18,111 shares in the last quarter. New York State Common Retirement Fund increased its position in shares of Insulet by 14.0% in the third quarter. New York State Common Retirement Fund now owns 71,585 shares of the medical instruments supplier’s stock valued at $3,943,000 after buying an additional 8,785 shares in the last quarter. Finally, Dynamic Technology Lab Private Ltd purchased a new position in shares of Insulet in the third quarter valued at $524,000.
Insulet Company Profile
Insulet Corporation is engaged in the development, manufacturing and sale of the OmniPod Insulin Management System (the OmniPod System), an insulin delivery system for people with insulin-dependent diabetes. The Omnipod System features a self-adhesive disposable tubeless Omnipod device, which is worn on the body for approximately three days at a time and its wireless companion, the handheld Personal Diabetes Manager (PDM).
Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.